425 related articles for article (PubMed ID: 16624482)
21. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.
Gorgoulis VG; Zacharatos P; Kotsinas A; Liloglou T; Kyroudi A; Veslemes M; Rassidakis A; Halazonetis TD; Field JK; Kittas C
Am J Pathol; 1998 Dec; 153(6):1749-65. PubMed ID: 9846966
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.
Sgambato A; Migaldi M; Faraglia B; De Aloysio G; Ferrari P; Ardito R; De Gaetani C; Capelli G; Cittadini A; Trentini GP
Int J Cancer; 2002 Feb; 97(5):671-8. PubMed ID: 11807796
[TBL] [Abstract][Full Text] [Related]
23. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma.
Lee K; Jung ES; Choi YJ; Lee KY; Lee A
J Korean Med Sci; 2010 Oct; 25(10):1449-55. PubMed ID: 20890425
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
[TBL] [Abstract][Full Text] [Related]
26. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
[TBL] [Abstract][Full Text] [Related]
27. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma.
Jayasurya R; Francis G; Kannan S; Lekshminarayanan K; Nalinakumari KR; Abraham T; Abraham EK; Nair MK
Int J Cancer; 2004 May; 109(5):710-6. PubMed ID: 14999779
[TBL] [Abstract][Full Text] [Related]
28. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
Eymin B; Gazzeri S; Brambilla C; Brambilla E
Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
[TBL] [Abstract][Full Text] [Related]
29. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade.
Burger M; Denzinger S; Hartmann A; Wieland WF; Stoehr R; Obermann EC
Br J Cancer; 2007 Jun; 96(11):1711-5. PubMed ID: 17505513
[TBL] [Abstract][Full Text] [Related]
30. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
31. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
33. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours.
Gugger M; Kappeler A; Vonlanthen S; Altermatt HJ; Ris HB; Lardinois D; Borner MM; Heighway J; Betticher DC
Lung Cancer; 2001; 33(2-3):229-39. PubMed ID: 11551418
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
35. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
[TBL] [Abstract][Full Text] [Related]
36. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
38. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder.
Moonen L; Ong F; Gallee M; Verheij M; Horenblas S; Hart AA; Bartelink H
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1305-10. PubMed ID: 11286838
[TBL] [Abstract][Full Text] [Related]
40. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
